
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Q It seems that my patients are becoming larger, stronger, and more belligerent. Recently, a number of patients 9 to 16 years of age became uncooperative and actually combative when we performed procedures such as fingersticks for hemoglobin tests or administered vaccines.






